These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27956417)

  • 41. Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays.
    Yao K; Zhang L; Zhou H; Tang N; Li D
    Am J Med Sci; 2017 Jul; 354(1):22-26. PubMed ID: 28755727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coagulation status after therapeutic plasma exchange using citrate in kidney transplant recipients.
    Yamada C; Pipe SW; Zhao L; Leichtman AB; Samaniego M; Sung RS; Davenport RD
    Transfusion; 2016 Dec; 56(12):3073-3080. PubMed ID: 27601087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
    Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
    Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
    Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
    Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.
    Shirts BH; Rodgers GM; Smock KJ
    Thromb Res; 2012 Sep; 130(3):e134-8. PubMed ID: 22542363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM).
    Thölking G; Mesters R; Dittrich R; Pavenstädt H; Kümpers P; Reuter S
    PLoS One; 2015; 10(6):e0130402. PubMed ID: 26121484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J; Chatelain C; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
    Harenberg J; Giese C; Knödler A; Zimmermann R
    Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels.
    Reed RL; Bracey AW; Hudson JD; Miller TA; Fischer RP
    Circ Shock; 1990 Oct; 32(2):141-52. PubMed ID: 2253317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact.
    Dirkmann D; Britten MW; Pauling H; Weidle J; Volbracht L; Görlinger K; Peters J
    Anesthesiology; 2016 Jun; 124(6):1277-85. PubMed ID: 26950705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.